In direct compression of veterinary tablets, the dried yeast API with a protein content of 40.0–50.0% w/w and β-glucan fraction of 5.0–10.0% w/w behaves primarily as a plastic deformer. Loss on drying by USP <731> should be held between 5.0% and 7.0% w/w for a 16-station B-tooling rotary press; material below 4.5% LOD produces variable ejection force and may chip tablet edges at 10–15 kN compression force, while material above 8.0% LOD adheres to punch faces and requires an increase in magnesium stearate to 1.0% w/w, which in turn extends disintegration. A representative direct compression batch comprises 35.0–55.0% w/w dried yeast API, 35.0–55.0% microcrystalline cellulose, 2.0–5.0% crospovidone, 0.5–2.0% colloidal silicon dioxide, and 0.5–1.0% magnesium stearate. The sequence in a 100 L V-blender at 25 rpm includes 10 min API-filler-disintegrant blending, 5 min blending after silicon dioxide addition, and 3 min after magnesium stearate. Tablets compressed at 10–14 kN to hardness 70–90 N exhibit friability below 1.0% and disintegration by USP <701> in 37±2°C water below 15 min. Weight uniformity must meet USP <905> acceptance value ≤15.0. The terminal product is a non-coated oral tablet for companion animal or livestock administration intended for delivery of 100–500 mg dried yeast per unit.

Why Does Parenteral Grade Yeast Polysaccharide Fail Terminal Sterilisation Above 121°C?

Whole-cell dried yeast is not a viable injectable input; only purified yeast-derived polysaccharide fractions, principally β-(1,3)/(1,6)-glucan, are evaluated for parenteral veterinary formulations. The processing barrier is thermal degradation. Terminal sterilisation above 121°C for a full 15 min cycle accelerates Maillard degradation between residual yeast protein and reducing carbohydrate residues, shifting the solution from pale straw to amber and reducing soluble β-glucan recovery by up to 15–25% when measured by Congo red spectral shift or equivalent carbohydrate-binding assay. Consequently, aseptic filtration through a 0.45 µm polyethersulfone prefilter followed by a 0.22 µm sterilising-grade PVDF membrane is the preferred route, with filtration train integrity tested by bubble point before and after batch transfer. The bulk solution typically contains 0.5–2.0 mg/mL purified yeast β-glucan, 0.9% w/v sodium chloride, and water for injection adjusted to pH 5.0–5.5 with hydrochloric acid or sodium hydroxide. Endotoxin control is dose-dependent under USP <85>; because β-glucan can produce false-positive or masked LAL interference, sample dilution and inhibition/enhancement screening are required before release. Sterility must comply with USP <71>; subvisible particulate counts must meet USP <788> limits for the labelled container volume. The terminal product is a clear or slightly opalescent solution filled in 10 mL or 50 mL borosilicate vials under nitrogen overlay, with shelf-life assigned only after real-time particulate and potency monitoring. Filtrate flux typically falls by 40–60% after 200 L/m² when high-molecular-mass aggregates exceed 300 nm hydrodynamic diameter; process validation therefore includes transmembrane pressure trending and post-use filter integrity rather than fixed batch volume. Published data for this specific yeast fraction in veterinary parenteral products is limited; process limits are therefore derived from filter validation and compendial sterility requirements.

When fill weight exceeds 250 mg in a size 1 capsule, the flow and compressibility of the dried yeast API determine the choice between dosator and tamping-pin filling. Bulk density for dried yeast veterinary powder typically ranges from 0.45 g/cm³ to 0.65 g/cm³, and Carr index values above 30% prevent consistent dosator pin retention on a 12,000 capsules/h semiautomatic machine. A preblend containing 55.0–70.0% w/w dried yeast API, 20.0–35.0% lactose monohydrate, 1.0–2.0% colloidal silicon dioxide, and 0.5–1.0% magnesium stearate is milled through a 0.8 mm conical screen before filling. Loss on drying by USP <731> must be below 6.0% w/w; at ambient relative humidity above 60%, the powder bed absorbs moisture and can adhere to the dosator pin, causing fill weight RSD to exceed 4.0%. Hard gelatin and HPMC capsules both require moisture limits in the shell: 13.0–16.0% for hard gelatin and 4.0–7.0% for HPMC. Capsule weight variation is assessed by USP <905>; disintegration by USP <701> with discs. The terminal product is an oral capsule containing 125–500 mg dried yeast API, used in dogs, cats, or calves, with a content uniformity acceptance value ≤15.0 and a yeast viability specification of ≥1.0×10⁹ CFU/g at release when the product is labelled as a live yeast probiotic.

Controlling Wet Mass Torque During High-Shear Granulation of Yeast Formulations

High-dose yeast tablets intended for oral administration are frequently produced by high-shear wet granulation because direct compression becomes impractical when the active fraction exceeds 55.0% w/w and dry blend flow is poor. The granulation endpoint is controlled by impeller power consumption rather than visual appearance. In a 10 L vertical high-shear granulator with a main impeller at 300 rpm and chopper at 1,500 rpm, dry premix containing 60.0–80.0% w/w dried yeast API, 10.0–25.0% microcrystalline cellulose, and 5.0–10.0% lactose monohydrate is preblended for 5 min. Binder fluid is added at a rate of 40–60 g/min; a typical binder is 5.0% w/w povidone K30 in purified water, used at 18.0–25.0% w/w relative to dry powder mass. The target endpoint is a torque plateau equivalent to 35–45% of the drive motor load. Overgranulation is identified by a temperature rise above 35°C in the wet mass and a rapid torque increase beyond 50% motor load, producing dense granules that resist milling and delay disintegration. Wet granules are passed through a 2.0 mm screen, dried in a fluid-bed unit at 60°C inlet air to 2.5–4.0% LOD, then dry-milled through a 0.8 mm screen. Tablets compressed at 12–16 kN to hardness 60–90 N meet USP <701> disintegration below 15 min and USP <905> uniformity. The terminal product is a film-coated or uncoated tablet for swine or equine use, with each unit delivering 500–1,000 mg dried yeast equivalent.

When Premix Coefficient of Variation Exceeds 5.0% After 10-Minute Ribbon Blending

Dried yeast API used as a direct-fed microbial in veterinary feed premixes is handled at low inclusion and requires carrier-mediated dilution to maintain mixing accuracy. A typical premix contains 5.0–20.0% w/w dried yeast API on a calcium carbonate or ground corn cob carrier, with a final viable yeast concentration of ≥1.0×10⁹ CFU/g. The mixture is prepared in a ribbon blender filled to 60–80% of geometric capacity, with a mixing time of 10 min at 25 rpm. Sampling for homogeneity follows ISO 6497 procedures, with ten discrete samples drawn from defined locations; the coefficient of variation for yeast count must not exceed 5.0%. Above 5.0% CV, segregation arises from particle size mismatch between the dried yeast API and carrier, and the correction involves introducing an intermediate preblend or reducing carrier mean particle size below 500 µm. Moisture is controlled below 8.0% w/w because free water accelerates caking and viability loss during storage. The terminal product is a 25 kg bagged premix added to complete feed at 1.0–5.0 kg/tonne, intended for swine, poultry, or ruminant rations, and labelled for viable yeast count, moisture, and mycotoxin control within FDA 21 CFR 225 good manufacturing practice requirements for medicated feed premix facilities.

Oral Solution Vehicle Parameters and Suspension Re-Dispersibility

Dried yeast API for oral solutions or suspensions is formulated as a dry powder for reconstitution rather than a ready-to-use suspension because of limited aqueous stability and microbial growth risk. The vehicle contains 0.5% w/v sodium carboxymethylcellulose as suspending agent, 0.1% w/v polysorbate 80 as wetting agent, 0.1% w/v sodium benzoate as preservative, and 0.1% w/v citric acid monohydrate to maintain pH 4.5–5.5. The dry powder is screened through 0.5 mm mesh and blended with sucrose or sorbitol to a final concentration of 100 mg dried yeast per 5 mL after reconstitution with purified water. Re-dispersibility requires that sediment formed after 24 h can be resuspended within 5 inversions; a sedimentation volume below 0.85 indicates flocculation or compacted caking and requires reduction of API particle size below 100 µm or an increase in CMC sodium viscosity to 50–100 mPa·s at 25°C. Preservative efficacy is evaluated by USP <51>, and microbial limits by USP <1111> for oral veterinary products. The terminal product is a 100 mL or 200 mL amber PET bottle with a dosing syringe, intended for neonatal calves or foals, with a reconstituted shelf-life of 7 days under refrigeration.